Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial - Hofman, MS; Emmett, L; Sandhu, S (Lancet Oncol, 2024)